Home | Life Sciences Intellectual Property Review
WEB5 days ago · 5 September 2024 Firm adds pair to its Washington DC office | Both bring experience in patent counselling and IP transactions | Expertise in biotech, life sciences, pharmaceutical sectors, consumer products, biomedical, chemical, food science, agriculture, and medical devices. 3 September 2024 The Unified Patent Court’s first decisions from ...
Latest News & Features | Life Sciences Intellectual Property Review
WEBSep 3, 2024 · Brown Rudnick expands with new partner duo. Firm adds pair to its Washington DC office | Both bring experience in patent counselling and IP transactions | Expertise in biotech, life sciences, pharmaceutical sectors, consumer products, biomedical, chemical, food science, agriculture, and medical devices. 5 …
Generics | Life Sciences Intellectual Property Review
WEBThe pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP. 28 March 2024 Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions ...
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Biotechnology | Life Sciences Intellectual Property Review
WEB21 May 2024 Despite attempts by Pfizer and BioNTech to invalidate the patent, the ruling strengthens Moderna’s position in ongoing global litigation | Pfizer is considering an appeal, while BioNTech remains steadfast in defending its innovations. 16 May 2024 Puritan Medical argued it had immunity under PREP Act in patent suit | Fed Circ said ...
Unified Patent Court | Life Sciences Intellectual Property Review
WEB12 December 2023 Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 28 November 2023 UPC judge, EPO director and Regeneron counsel shed light on the court’s dynamics at London event | Life sciences sector emerging as a major player in the ...
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
EPO’s new examination guidelines: what you need to know
WEBApr 6, 2021 · A new edition of the European Patent Office (EPO) Guidelines for Examination came into force on March 1, 2021. Relevant to life sciences, this edition includes a new subsection detailing EPO practice with respect to the interpretation of terms relating to amino or nucleic acid sequences, as well as a new section on the examination of claims to antibodies.
FTC endorses greater access to affordable biosimilars
WEBAug 22, 2024 · FTC backs FDA's proposals to streamline approval process for interchangeable biosimilars | Move aims to lower prescription drug costs and expand access to critical treatments | FTC emphasises the new guidance could create competition in the biologics market and save US healthcare billions of dollars.
Magazine Archive | Life Sciences Intellectual Property Review
WEBMagazine Archive. Click the thumbnails below to view the Life Sciences IP Review magazines. LSIPR Spring/Summer 2022. Spring is here and the UK government is marking it by airing its Genetic Technology (Precision Breeding) Bill, promising to breathe new life into an area apparently suffocated by EU red tape. LSIPR new recruit Sarah Speight asks ...